In this webinar, we present Biointron's proven expertise in two discovery approaches: VHH Phage Display for single-domain antibody generation and AbDrop Single B Cell Screening for rapid antibody discovery.
Successful antibody discovery requires more than just access to powerful platforms - it demands the experience to apply them efficiently and strategically. Representative case studies are discussed to illustrate how Biointron's seasoned scientific team overcomes technical hurdles, tackles challenging targets, shortens discovery timelines, and consistently delivers high-quality antibodies, thus offering a reliable path from target to candidate.
Presenters

Gang Liu
Dr. Gang Liu is Director of Discovery Services at Biointron, and has devoted himself to biological sciences and antibody therapeutics research for more than 20 years. Before joining Biointron, Dr. Liu worked in renowned biotech such as Genscript, and prestigious academic institutions, including Children's Hospital LA, UC Irvine, and City of Hope Medical Center. Dr. Liu earned his Ph.D. degree from Academy of Military Medical Sciences in China, 2007, specializing in cancer research.
Sponsor

Biointron
Content Partners

Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

































































































